These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 17666193)

  • 1. Prevention of stroke in patients with hypertension.
    Dahlöf B
    Am J Cardiol; 2007 Aug; 100(3A):17J-24J. PubMed ID: 17666193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading?
    Oparil S; Kjeldsen SE; Hedner T; Narkiewicz K
    Blood Press; 2009; 18(1-2):4-6. PubMed ID: 19191085
    [No Abstract]   [Full Text] [Related]  

  • 3. Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?
    Serebruany VL; Atar D; Hanley DF
    Cerebrovasc Dis; 2008; 26(5):563-4. PubMed ID: 18936537
    [No Abstract]   [Full Text] [Related]  

  • 4. [Telmisartan (micardis) -- an antagonist of angiotensin 2 of type 1 receptors: another antihypertensive drug or something greater?].
    Chazova IE
    Ter Arkh; 2003; 75(6):89-91. PubMed ID: 12920969
    [No Abstract]   [Full Text] [Related]  

  • 5. [In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension].
    MMW Fortschr Med; 2006 Jun; 148(26):50-1. PubMed ID: 16875381
    [No Abstract]   [Full Text] [Related]  

  • 6. Choosing an angiotensin-receptor blocker: blood pressure lowering, cardiovascular protection or both?
    Neldam S
    Future Cardiol; 2010 Jan; 6(1):129-35. PubMed ID: 20014992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospects for the prevention of stroke.
    Dahlöf B
    J Hypertens Suppl; 2006 Apr; 24(2):S3-9. PubMed ID: 16601558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?
    Ong HT
    J Am Board Fam Med; 2009; 22(6):686-97. PubMed ID: 19897698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of fixed dose combination (FDC) of telmisartan+ramipril usage in patients with micro-albuminuria and persistent hypertension: A TRIUMPH study.
    Sharma A; Baliga V;
    J Indian Med Assoc; 2008 Mar; 106(3):191-4, 196. PubMed ID: 18712142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ventricular hypertrophy and hypertension: prognostic elements and implications for management.
    Krauser DG; Devereux RB
    Herz; 2006 Jun; 31(4):305-16. PubMed ID: 16810470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypertension treatment and implications of recent cardiovascular outcome trials.
    Weber MA
    J Hypertens Suppl; 2006 Apr; 24(2):S37-44. PubMed ID: 16601560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension--a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months rationale and study design.
    Friedrich MG; Dahlöf B; Sechtem U; Unger T; Knecht M; Dietz R;
    J Renin Angiotensin Aldosterone Syst; 2003 Dec; 4(4):234-43. PubMed ID: 14689371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventing stroke: the PRoFESS, ONTARGET, and TRANSCEND trial programs.
    Diener HC
    J Hypertens Suppl; 2009 Jul; 27(5):S31-6. PubMed ID: 19587553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
    Yamagishi S; Takeuchi M
    Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale for double renin-angiotensin-aldosterone system blockade.
    Unger T; Stoppelhaar M
    Am J Cardiol; 2007 Aug; 100(3A):25J-31J. PubMed ID: 17666194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ONTARGET/TRANSCEND Trial Programme: baseline data.
    Sleight P
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S50-6. PubMed ID: 15868120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Achieving blood pressure goals: should angiotensin II receptor blockers become first-line treatment in hypertension?
    Weber M
    J Hypertens Suppl; 2009 Jul; 27(5):S9-14. PubMed ID: 19587555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of telmisartan plus amlodipine in the treatment of hypertension: review of results.
    Oigman W; Neves MF; Gismondi RA
    Expert Rev Cardiovasc Ther; 2010 Nov; 8(11):1509-17. PubMed ID: 21090924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [In the DETAIL. Kidney protection in manifestations of microalbuminuria].
    MMW Fortschr Med; 2006 Jun; 148(26):51. PubMed ID: 16875382
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.